Enoxaparin Sodium Injection Obtains South African Drug Registration Approval
April 28, 2025
Source: drugdu
83
Hepalink announced on the evening of April 24 that its wholly-owned subsidiary Tiandao Pharmaceutical recently received an approval notice for Enoxaparin Sodium Injection issued by the South African Health Products Administration. The drug can be used before and after surgery to prevent or prevent blood clots in the blood. This approval means that Hepalink's Enoxaparin Sodium preparations can be sold in the South African market. Hepalink disclosed its first quarter report for 2025 on the same day, with a net profit attributable to shareholders of 157 million yuan in the first quarter, a year-on-year increase of 1%.
https://finance.eastmoney.com/a/202504243387456384.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Humanwell Pharmaceuticals’ RFUS-949 tablet clinical trial approved May 31, 2025
- The clinical trial of STC007 injection of Sunshine Novo’s subsidiary has achieved the expected goal May 31, 2025
- The National Medical Products Administration conditionally approved the marketing of Trastuzumab for injection May 31, 2025
- Moderna withdraws its application for the launch of the new crown/influenza combined vaccine, and its share price fell more than 6% during the session May 31, 2025
- Jimin Health’s hospitals and Dabo Biotech signed a strategic cooperation agreement to expand the layout of cell and gene therapy pipeline May 31, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
